IFNA2 and cryohydrocytosis: The results of our study show that, when used in the treatment of patients with CHC and associated rheumatoid syndrome, Peg-IFNα2a anti-inflammatory activity can improve the rheumatic manifestations by down-regulating the inflammation markers and reducing the rheumatic inflammatory symptoms.